U.S. markets closed

PolarityTE, Inc. (PTE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5200+0.0700 (+4.83%)
At close: 04:00PM EDT
1.5300 +0.01 (+0.66%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4500
Bid1.4700 x 1000
Ask1.5300 x 1300
Day's Range1.4200 - 1.5300
52 Week Range1.4100 - 23.7500
Avg. Volume394,355
Market Cap6.106M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-6.3120
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 12, 2016
1y Target Est23.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PTE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PolarityTE, Inc.
    VCEL: Raising target price to $66.00VERICEL CORP has an Investment Rating of HOLD; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

    PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Pol

  • PR Newswire

    PolarityTE to Attend H.C. Wainwright Global Investment Conference

    PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.

  • PR Newswire

    PolarityTE to Effectuate 1-for-25 Reverse Stock Split

    PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022. As of that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. A new CUSIP number has